Has anyone invested in KNSA since the trial came out showing that GM-CSF is the key to Covid? It seems likely that the government will put money toward an additional trial that includes several different drugs that are anti-GM-CSF. Lenz is obviously the top of the list. But Kiniksa's drug mavrilimumab also has a lot of potential. And their stock is down the last couple of sessions despite announcing FDA approval for recurrent pericarditis last Thursday night. I guess the news was already baked in but it should have popped a bit. No one on the KNSA stocktwits page is even talking about Covid treatment.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.